The Generic Drugs Market: 2015 – 2030 - Opportunities, Challenges, Strategies & Forecasts

Release Date: February 2015
Number of Pages: 249
Number of Tables and Figures: 54

Synopsis: A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights.

Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs.

SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets.
The “Generic Drugs Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
For a Sample and Table of Contents please contact info@snsintel.com

Pricing: The report is available for the following price: 

Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500

Company Wide License (Global Site): USD 6,500

Key Findings:
The report has the following key findings:
  • Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years.
  • As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan.
  • In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs.
  • In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia.
  • Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020.

Topics Covered:
The report covers the following topics:
  • Generic drugs ecosystem
  • Market drivers and barriers
  • Technology, economics and key trends
  • Pure, branded and super generics
  • Analysis of key therapeutic areas and leading generic drugs
  • Regulatory landscape of generic drugs throughout the globe
  • Industry roadmap and value chain
  • Profiles and strategies of over 130 leading ecosystem players, including generic and innovator drug manufacturers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2015 till 2030

Historical Revenue & Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Brand Classification
    • Pure (Non-branded) Generics
    • Branded Generics
    • Super Generics
  • Therapeutic Area
    • Antibiotics
    • Cardiovascular & Hypertension
    • CNS (Central Nervous System)
    • Dermatology
    • Diabetes
    • Gastrointestinal
    • Hormonal Drugs
    • Oncology
    • Pain Relief
    • Respiratory
    • Rheumatology
    • Others
  • Regional Markets
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America
  • Country Markets
    • Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico
    • Netherlands
    • Poland
    • Portugal
    • Russia
    • Saudi Arabia
    • South Africa
    • South Korea
    • Spain
    • Switzerland
    • Taiwan
    • Turkey
    • UK
    • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the generic drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2020 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • How big is the market for generic cancer drugs?
  • How does regulation impact the adoption of generic drugs?
  • How will branded and super generics impact revenue prospects?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of biologics impact the market?
  • What are the future prospects of approved and non-approved biosimilar drugs?
  • What strategies should generic and innovator drug manufacturers adopt to remain competitive?

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:

Abbott Laboratories
AbbVie
ACETO Corporation
Acino Holding
Actavis
Actelion
Adcock Ingram
Aesica Pharmaceuticals
Ajinomoto
Akron
Alexion Pharmaceuticals
Alfa Wasserman
Allergan
Almirall
AMA (African Medicines Regulatory Agency)
Amgen
Amneal Pharmaceuticals
AMRI (Albany Molecular Research, Inc.)
ApoPharma 
Apotex
Arch Pharmalabs
ASKA Pharmaceutical Company
Aspen Holdings
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Auxilium Pharmaceuticals
Baxter BioScience
Baxter International 
Bayer AG
BD (Becton, Dickinson and Company)
BD Rx
Berlin Chemie
Biocon
Biogaran
Biogen Idec
Biogen Laboratorios
BMS (Bristol-Myers Squibb)
Boehringer Ingelheim
Boots UK
BPI (Breckenridge Pharmaceutical Inc.) 
Breckenridge Pharmaceutical 
Cadila Healthcare (Zydus Cadila)
Cadila Pharmaceuticals
CBER (Centre for Biologics Evaluation and Research)
CDER (Centre for Drug Evaluation and Research) 
CDSCO (Central Drug Standards and Control Organization, India)
Cedarburg Pharmaceuticals
Celgene Corporation
Celltrion Group
CFDA (China Food and Drug Administration)
Chiesi Farmaceutici
Chugai Pharmaceutical Company
Cipla
Claris Injectables
Claris Lifesciences
Claris Otsuka
Coherus BioSciences
Consort Medical
Covidien
Cubist Pharmaceuticals
Cypress Pharmaceutical
Daiichi Sankyo
Daiichi Sankyo Espha 
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Dusa Pharmaceuticals
EGA (European Generic Medicines Association) 
Egis Pharmaceuticals
Eisai Company
Eli Lilly and Company
Elmed Eisai Company 
EMA (European Medicines Agency)
Endo International
Endo Pharmaceuticals 
ESTEVE Farma 
ESTEVE Group
Eurofarma Laboratorios
FDA (Food and Drug Administration) 
Ferring Pharmaceuticals
Forest Laboratories
Fresenius Kabi
Fuji Pharma Company
Fujifilm Corporation 
Fujifilm Holdings Corporation
Fujifilm Pharma Company
Galderma
Galenika
Gedeon Richter
Gedeon Richter PregLem
Genepharm
GGL (Glenmark Generics Limited) 
Gilead Sciences
Glenmark Pharmaceuticals
Global Pharmaceuticals
Globalpharma
Grifols
Gruenenthal Group
GSK (GlaxoSmithKline)
Guangdong BeiKang Pharmaceutical Company
Hanmi Pharmaceutical Company
Health Canada
Hetero Drugs
Hikma Pharmaceuticals
Hi-Tech Pharmacal
Hospira
Impax Laboratories
Impax Pharmaceuticals
Ipsen
Janssen Pharmaceutica
Jazz Pharmaceuticals
JHP Group Holdings
JHP Pharmaceuticals
Johnson & Johnson
JT (Japan Tobacco)
Kaken Pharmaceutical Company
Kaneka Corporation
Kowa Company
Kowa Health Care America
Kowa Pharmaceuticals America
Kowa Research Institute
Kremers Urban Pharmaceuticals
Krka (Krka, d. d.)
Kyowa Hakko Kirin Company
Kyowa Pharmaceutical Industry Company
Laboratorios Roemmers
Leo Pharma
Les Laboratoires Servier
Lil Therapeutics
Lundbeck (H. Lundbeck A/S)
Lupin
Mallinckrodt
Maruho Company
Matrix Laboratories
Meda
Medley Farma
Meiji Holdings
Meiji Seika Pharma Company
Menarini Group
Merck and Co.
Merck KGaA
Merck Serono
Merz Pharma
Ministry of Health, Labour and Welfare (Japan)
Mitsubishi Chemical Holdings Corporation
Mitsubishi Tanabe Pharma
Mitsui & Company
Mitsui Group
MN (Mustafa Nevzat) Pharma
Mylan
Natco Pharma
Nichi-Iko Pharmaceutical Company
Nippon Kayaku
Nippon Shinyaku
Nipro Pharma Corporation
Novartis International
Novo Nordisk
OLIC (Thailand)
Ono Pharmaceutical Company
Orion Corporation
Osaka Synthetic Chemical Laboratories
Otsuka Holdings Company
Otsuka Pharmaceutical Company
Paladin Labs
Par Pharmaceutical Companies
Pensa Dose
Pensa Pharm
Perrigo Company
Pfizer
Pharma Dynamics
Pharmstandard
Pierre Fabre (Laboratoires Pierre Fabre)
Piramal Enterprises
Piramal Group
Pliva (Pliva d.d.)
Prasco Laboratories
PregLem
Purdue Pharma
Qualitest and Vintage Pharmaceuticals
Ranbaxy Laboratories
Recordati
Regeneron Pharmaceuticals
Rising Pharmaceuticals
Roche Holding (F. Hoffmann-La Roche)
Roxane Laboratories
Salix Pharmaceuticals
Samsung Bioepis
Samsung BioLogics 
Samsung Group
Sandoz International
Sanofi
Sanofi-Aventis Nichi-Iko K.K.
Santen Pharmaceutical Company
Sawai Pharmaceutical Company
Seikagaku Corporation
Sequent Scientific
Servier Group
Shionogi & Company
Shire
Sigma-Tau
Somar (Grupo Farmaceutico Somar)
STADA Arzneimittel
Strativa Pharmaceuticals
Strides Arcolab
Sumitomo Dainippon Pharma Company
Sun Pharmaceutical Industries
Supera Farma Laboratorios
Taisho Pharmaceutical Company
Taisho Pharmaceutical Holdings Company
Taisho Pharmaceutical Industries
Taiyo Pharmaceutical Industry Company
Takeda Pharmaceutical Company
Tanabe Seiyaku Hanbai Company
Taro Pharmaceutical Industries 
Teijin
Teijin Pharma 
Teva Pharmaceutical Industries
Teva-Kowa Pharma Company
The Medicines Company
Torrent Group
Torrent Pharmaceuticals
Towa Pharmaceutical Company
UCB
United Therapeutics Corporation
Valeant Pharmaceuticals International
Ventana Medical Systems
Vertex Pharmaceuticals
Warner-Chilcott
West-Ward Pharmaceuticals 
WHO (World Health Organization)
Wockhardt
Zentiva